You are at the center of everything we do at Seattle Cancer Care Alliance (SCCA). Here, we surround you with a team of specialists who work together closely to provide collaborative care and compassionate support throughout your treatment.
Our experts evaluate and treat all types of amyloidosis. We guide you every step of the way, combining our deep clinical expertise with a commitment to meet your unique needs.
Request an appointment
Why choose SCCA for amyloidosis treatment?
Amyloidosis is not considered cancer. But the most common type (light chain amyloidosis, or AL) is caused by abnormal plasma cells. It is similar to cancer of the plasma cells (multiple myeloma) and involves similar treatments. This is why amyloidosis experts, like ours at SCCA, are often cancer doctors (hematologist-oncologists).
Experienced diagnosis and care
Because amyloidosis is so rare, most hematologist-oncologists in the community see only one or two people with this condition in their entire career. At SCCA, we’ve seen more than 300 new patients with primary or secondary amyloidosis in the past five years — experience that translates into state-of-the-art diagnosis and care for you.
Comprehensive amyloidosis treatment
Team-based care is essential if amyloidosis affects tissues and organs throughout your body, as it often does. SCCA brings together UW Medicine doctors from multiple fields, including hematology/oncology, cardiology, nephrology, neurology and others, to provide multidisciplinary treatment.
Advancing new approaches
Along with offering standard chemotherapies and targeted therapies, we’re involved in amyloidosis clinical trials to develop new treatments, such as amyloid-removing agents. To advance care for patients everywhere, we collaborate with amyloidosis experts at other treatment centers, including Mayo Clinic and Boston University.
Bone marrow transplant for amyloidosis
The Fred Hutch Bone Marrow Transplant Program at SCCA consistently achieves higher-than-expected transplant survival rates. We’ve performed more bone marrow and stem cell transplants than any other institution in the world. Since 2001, we’ve transplanted 60 people with amyloidosis.
NCI comprehensive cancer center
We are a comprehensive cancer center, a designation from the National Cancer Institute that reflects our scientific leadership and the depth and breadth of our research to prevent, diagnose and treat cancer. Our doctors and scientists bring the same commitment to amyloidosis and other blood-related diseases.